Media stories about Thermo Fisher Scientific (NYSE:TMO) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Thermo Fisher Scientific earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.8286580058813 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- AGCO Corporation (AGCO) Ex-Dividend Date Scheduled for February 14, 2018 – Nasdaq (nasdaq.com)
- Medtronic’s Fiscal 3Q18 Results: What to Expect (finance.yahoo.com)
- Lindsay Corporation (LNN) Ex-Dividend Date Scheduled for February 13, 2018 – Nasdaq (nasdaq.com)
- Graham Corporation (GHM) Ex-Dividend Date Scheduled for February 13, 2018 – Nasdaq (nasdaq.com)
- Why it’s important to understand technical analysis of Thermo Fisher Scientific Inc. (TMO)? – Wall Street Morning (wallstreetmorning.com)
Thermo Fisher Scientific (TMO) traded up $0.78 during mid-day trading on Thursday, hitting $209.09. 403,872 shares of the stock were exchanged, compared to its average volume of 1,637,221. Thermo Fisher Scientific has a one year low of $151.74 and a one year high of $226.44. The company has a market cap of $83,800.00, a PE ratio of 37.32, a PEG ratio of 1.49 and a beta of 1.11. The company has a quick ratio of 0.92, a current ratio of 1.35 and a debt-to-equity ratio of 0.74.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.33%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.71%.
TMO has been the topic of a number of recent research reports. Leerink Swann reaffirmed an “outperform” rating and issued a $239.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Barclays boosted their price target on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Bank of America upped their target price on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Two investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $220.50.
In other news, SVP Gregory J. Herrema sold 33,327 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the sale, the senior vice president now owns 60,471 shares in the company, valued at approximately $13,285,478.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the transaction, the chief executive officer now owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The disclosure for this sale can be found here. In the last three months, insiders have sold 94,327 shares of company stock worth $19,260,542. Insiders own 0.49% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Thermo Fisher Scientific (TMO) Getting Somewhat Positive Press Coverage, Study Finds” was reported by Week Herald and is owned by of Week Herald. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://weekherald.com/2018/02/15/thermo-fisher-scientific-tmo-receives-daily-media-sentiment-score-of-0-12.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.